by Admin | May 17, 2023 | Portfolio News
Previously announced $85 million financing extended by $50 million BOSTON, May 16, 2023 – Ensoma, a genomic medicines company developing one-time, in vivo treatments that precisely engineer any cell of the hematopoietic system, today announced the...
by Admin | Mar 7, 2023 | Portfolio News
SAN DIEGO, March 6, 2023 /PRNewswire/ — Phanes Therapeutics, Inc., a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced that it has entered into a research collaboration with Xyphos...
by Admin | Dec 5, 2022 | Portfolio News
近日,据悉三叶草生物(香港联交所股票代码:02197)旗下领先的新冠疫苗SCB-2019(CpG1018/铝佐剂)经国家有关部门评估后被纳入紧急使用。 三叶草生物开发了SCB-2019抗原——一种基于SARS-CoV-2(新冠病毒)原始毒株S蛋白的稳定的三聚体结构融合蛋白(S-三聚体™)。其新冠疫苗SCB-2019(CpG1018/铝佐剂)是由SCB-2019抗原联合两种佐剂,即Dynavax的CpG 1018佐剂及氢氧化铝(铝佐剂)组成。 据三叶草生物全球五个国家入组超过3万名受试者的“SPECTRA” II/III...
by Admin | Nov 30, 2022 | Portfolio News
Funding will support development of lead assets and enhance target discovery and platform development CAMBRIDGE, Mass., Nov. 29, 2022 /PRNewswire/ — Rgenta Therapeutics Inc. announced today that it closed a $52 million Series A round led...
by Admin | Nov 3, 2022 | Portfolio News
Boston/Shanghai/November 3rd, 2022 — Eccogene announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to commence a Phase I trial of its glucagon-like peptide 1 receptor agonist (GLP-1 RA) ECC5004...
by Admin | Oct 14, 2022 | Portfolio News
美国圣地亚哥,中国上海、广东松山湖 2022年10月14日,专注于肿瘤领域的临床阶段生物技术公司凡恩世公司(Phanes Therapeutics)今天宣布,其DLL3/CD47双特异性抗体(双抗)PT217获得美国食品药品监督管理局(FDA)临床试验批准,将在小细胞肺癌(SCLC)和其他神经内分泌癌患者中开展I期临床试验。PT217近期也已获FDA孤儿药资格认定。...